Sofgen Pharma (PROC.F) Stock Overview
Develops, produces, and markets pharmaceutical solutions in South America, Central America, North America, and Europe. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
PROC.F Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Sofgen Pharma S.A. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.10 |
| 52 Week High | US$1.47 |
| 52 Week Low | US$0.0011 |
| Beta | 62.19 |
| 1 Month Change | 313.22% |
| 3 Month Change | -90.29% |
| 1 Year Change | -93.20% |
| 3 Year Change | -97.95% |
| 5 Year Change | -99.01% |
| Change since IPO | -98.98% |
Recent News & Updates
Recent updates
These 4 Measures Indicate That Procaps Group (NASDAQ:PROC) Is Using Debt Extensively
Mar 28
Is Procaps Group S.A. (NASDAQ:PROC) Worth US$3.7 Based On Its Intrinsic Value?
Feb 02Calculating The Intrinsic Value Of Procaps Group S.A. (NASDAQ:PROC)
Feb 01Procaps Group reports Q2 results
Aug 30Calculating The Fair Value Of Procaps Group, S.A. (NASDAQ:PROC)
Jan 10Shareholder Returns
| PROC.F | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | -9.1% | 3.8% | 3.5% |
| 1Y | -93.2% | 37.2% | 31.0% |
Return vs Industry: PROC.F underperformed the US Pharmaceuticals industry which returned 29.6% over the past year.
Return vs Market: PROC.F underperformed the US Market which returned 23.7% over the past year.
Price Volatility
| PROC.F volatility | |
|---|---|
| PROC.F Average Weekly Movement | n/a |
| Pharmaceuticals Industry Average Movement | 10.0% |
| Market Average Movement | 7.1% |
| 10% most volatile stocks in US Market | 16.4% |
| 10% least volatile stocks in US Market | 3.3% |
Stable Share Price: PROC.F's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: Insufficient data to determine PROC.F's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1977 | 4,498 | Melissa Angelini | www.sofgenpharma.com |
Sofgen Pharma S.A., together with its subsidiaries, develops, produces, and markets pharmaceutical solutions in South America, Central America, North America, and Europe. It operates in five segments: NextGel, Procaps Colombia, Central America North (CAN), Central America South and North Andes (CASAND), and Diabetrics. The company develops and manufactures Softgel and related technologies under the Softigel, Sofgen, Softcaps, and Funtrition brands; and Softgel pharmaceutical products, such as Advil, Apronax Liquidgels, multivitamins, Vitamin D, and Dolex ActivGel.
Sofgen Pharma S.A. Fundamentals Summary
| PROC.F fundamental statistics | |
|---|---|
| Market cap | US$232.72m |
| Earnings (TTM) | -US$68.30m |
| Revenue (TTM) | US$373.80m |
Is PROC.F overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| PROC.F income statement (TTM) | |
|---|---|
| Revenue | US$373.80m |
| Cost of Revenue | US$182.32m |
| Gross Profit | US$191.48m |
| Other Expenses | US$259.78m |
| Earnings | -US$68.30m |
Last Reported Earnings
Dec 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.029 |
| Gross Margin | 51.23% |
| Net Profit Margin | -18.27% |
| Debt/Equity Ratio | -530.8% |
How did PROC.F perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/04/04 17:09 |
| End of Day Share Price | 2026/04/02 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Sofgen Pharma S.A. is covered by 2 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Brian Kemp Dolliver | Brookline Capital Markets |
| Samuel Campos Alves | BTG Pactual |